tbuckley/cabot-search huggingface dataset:
OP0191-HPR Usability Study of A New Auto-Injector in The Management of Rheumatoid Arthritis
Authors: C. Hudry, A. Lebrun, B. Moura, O. Backers, H. Herman-Demars
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease, for which the introduction of injectable treatments has had a major impact on quality of life. However, patients with RA may suffer from reduced manual dexterity, meaning that administering self-injections can be physically problematic. <h3>Objectives</h3> The primary objective of this French multicenter study was to evaluate the usability of a new auto-injector, based on the device design and instructions for use (IFU). <h3>Methods</h3> Three groups of subjects were enrolled in the trial: i/ professional nurses or caregivers; ii/ patients with established RA diagnosis with moderate to severe and iii/ from mild hand disability to normal hand function (assessed by Cochin scale above or fewer than 20, respectively). Injections (inj.) were performed with a water-filled device on a foam pad mimicking skin behavior. Each subject performed three inj. in different conditions (first phase (one inj.): just after reading the IFU without further instructions; second phase after explanations upon user9s request (two inj.): first in an optimum environment then in a "worst case" environment (noise, dimmed light etc.)). The usability of the auto-injector was assessed by a questionnaire (success: ≥75% of positive responses) and by a score card reflecting injection performances, assessed by an independent observer (success: execution of ≥75% of handling steps). <h3>Results</h3> 42 subjects were enrolled in the study between November 2014 and March 2015. There were no major differences in subject profiles (group size, age, sex) between the 3 user groups. During the first phase, the great majority of subjects succeeded in the usability questionnaire (90.5%) and in the inj. performance (95.2%) with no major differences between the user groups. In the second phase, all subjects from all 3 user groups succeeded in the usability questionnaire and had a positive rate of device handling, regardless of the environment and of the user group. No safety concerns were raised during the study. <h3>Conclusions</h3> This study found a very high level of usability and subject acceptance of the auto-injector, regardless of the hand disability. The high performance rate in the first phase showed an intuitive device handling. The study also emphasized the importance of instructions provided to the patient for a 100% understanding and handling success. <h3>Disclosure of Interest</h3> C. Hudry Consultant for: Nordic Pharma, A. Lebrun Consultant for: Nordic Pharma, B. Moura Consultant for: Nordic Pharma, O. Backers Employee of: Disphar international, H. Herman-Demars Employee of: Nordic Pharma
Socioeconomic status and treatment outcomes for individuals with HIV on antiretroviral treatment in the UK: cross-sectional and longitudinal analyses
Authors: Lisa S Burch, Colette J Smith, Jane Anderson, Lorraine Sherr, Alison J Rodger, Rebecca O'Connell, Anna-Maria Geretti, Richard Gilson, Martin Fisher, Jonathan Elford, Martin Jones, Simon Collins, Yusef Azad, Andrew N Phillips, Andrew Speakman, Margaret A Johnson, Fiona C Lampe
Journal: The Lancet Public Health (2016)

BackgroundFew studies have assessed the effect of socioeconomic status on HIV treatment outcomes in settings with universal access to health care. Here we aimed to investigate the association of socioeconomic factors with antiretroviral therapy (ART) non-adherence, virological non-suppression, and virological rebound, in HIV-positive people on ART in the UK.MethodsWe used data from the Antiretrovirals, Sexual Transmission Risk and Attitudes (ASTRA) questionnaire study, which recruited participants aged 18 years or older with HIV from eight HIV outpatient clinics in the UK between Feb 1, 2011, and Dec 31, 2012. Participants self-completed a confidential questionnaire on sociodemographic, health, and lifestyle issues. In participants on ART, we assessed associations of financial hardship, employment, housing, and education with: self-reported ART non-adherence at the time of the questionnaire; virological non-suppression (viral load >50 copies per mL) at the time of questionnaire in those who started ART at least 6 months ago (cross-sectional analysis); and subsequent virological rebound (viral load >200 copies per mL) in those with initial viral load of 50 copies per mL or lower (longitudinal analysis).FindingsOf the 3258 people who completed the questionnaire, 2771 (85%) reported being on ART at the time of the questionnaire, and 2704 with complete data were included. 873 (32%) of 2704 participants reported non-adherence to ART and 219 (9%) of 2405 had virological non-suppression in cross-sectional analysis. Each of the four measures of lower socioeconomic status was strongly associated with non-adherence to ART, and with virological non-suppression (prevalence ratios [PR] adjusted for gender/sexual orientation, age, and ethnic origin: greatest financial hardship vs none 2·4, 95% CI 1·6–3·4; non-employment 2·0, 1·5–2·6; unstable housing vs homeowner 3·0, 1·9–4·6; non-university education 1·6, 1·2–2·2). 139 (8%) of 1740 individuals had subsequent virological rebound (rate=3·6/100 person-years). Low socioeconomic status was predictive of longitudinal rebound risk (adjusted hazard ratio [HR] for greatest financial hardship vs none 2·3, 95% CI 1·4–3·9; non-employment 3·0, 2·1–4·2; unstable housing vs homeowner 3·3, 1·8–6·1; non-university education 1·6, 1·1–2·3).InterpretationSocioeconomic disadvantage was strongly associated with poorer HIV treatment outcomes in this setting with universal health care. Adherence interventions and increased social support for those most at risk should be considered.FundingNational Institute for Health Research.
Haploidentical Allogeneic Transplantation Provides Comparable Outcomes to HLA-Matched or Mismatched Unrelated Donor Grafts in Hematological Malignancies
Authors: Melissa F Baker, Daniel Kim, Michele L Donato, Andrew L Pecora, David H. Vesole, Alan P Skarbnik, Barbara Adler-Brecher, Michele Boonstra, Brenda Diaz, Phyllis McKiernan, Pamela Sutherland, Scott D Rowley
Journal: Blood (2014)
Bortezomib (Velcade), Thalidomide, Dexamethasone and Panobinostat (VTD-P) Is a Safe, Well Tolerated and Efficacious Regimen for Patients with Relapsed Multiple Myeloma: Preliminary Results of the Muk-Six Trial
Authors: Rakesh Popat, Sarah R Brown, Louise M Flanagan, Andrew Hall, Bhuvan Kishore, Matthew Streetly, Heather E Oakervee, Simon L. Hallam, Matthew Smith, Kwee L Yong, Gordon Cook, James D. Cavenagh
Journal: Blood (2015)
Imatinib Therapy for Chronic Myeloid Leukemia: An Experience From Eastern India.
Authors: Swati Dasgupta, Ujjal Ray, Soma Mukhopadhyay, Chinmoy Kumar Bose, Sanjoy Sarkar, Firoj Gharami, Subhasish Dey, Jayasri Basak, Ashis Mukhopadhyay
Journal: Blood (2010)
Global Gene Expression in Leukemic Blasts as a Function of Germline Genetic Variation.
Authors: Deborah French, Mark R. Wilkinson, Wenjian Yang, Luc de Chaisemartin, Edwin H. Cook, Soma Das, Mark J. Ratain, William E. Evans, James R. Downing, Ching-Hon Pui, Mary V. Relling
Journal: Blood (2004)
OC-015 Nicorandil Does not Worsen Non-Variceal Upper Gastrointestinal Bleeding (NVUGIB) in Patients Taking Aspirin or Antithrombotic Drugs (ATDs): Abstract OC-015 Table 1
Authors: AS Taha, C McCloskey, T Craigen, A Simpson, WJ Angerson
Journal: Gut (2016)

<h3>Introduction</h3> Nicorandil is a vasodilatory drug that has the dual properties of a nitrate and K+ATP channel agonist. It is often added to ATDs in the management of angina. In light of some case reports, its manufacturer and the medicines regulatory agencies have issued cautions that it can cause mucosal ulcers, perforation and bleeding, and that these might be worse in users of aspirin. We therefore aimed to investigate the possibility that NVUGIB is more severe in patients using ATDs plus Nicorandil than ATDs alone. <h3>Methods</h3> Patients presenting with NVUGIB and using ATDs plus Nicorandil (n = 59) were compared to those using ATDs alone (Controls; n = 1056) with respect to haemoglobin level, Blatchford UGIB risk score, composite endoscopy score (covering lesions in the oesophagus, stomach and duodenum), need for blood transfusion, length of hospital admission, and 30 day mortality. ATDs included low dose aspirin, clopidogrel, dipyridamole, warfarin and heparin. <h3>Results</h3> Table 1, below, summarises the outcomes of NVUGIB and the characteristics of patients using ATDs alone vs. those using ATDs plus Nicorandil. Age and haemoglobin are shown as mean (SD), the other interval variables as median (interquartile range) and binary variables as percentage (number). The final column shows differences between groups (Nicorandil minus control) with 95% confidence intervals. All differences were statistically insignificant (P &gt; 0.05, Student’s t, Mann-Whitney and Fisher’s exact tests as appropriate). <h3>Conclusion</h3> Patients taking ATDs plus Nicorandil were well matched demographically with controls taking ATDs alone. The confidence intervals place a modest upper limit on any exacerbation of NVUGIB by Nicorandil as manifested by reduced haemoglobin and increased need for transfusion. The intake of Nicorandil does not seem to worsen the severity or the outcomes of NVUGIB. These findings, therefore, do not justify discontinuing Nicorandil in patients with angina and presenting with NVUGIB while taking ATDs. <h3>Disclosure of Interest</h3> None Declared
High-Resolution Analysis of the Relationship Between Dose and Molecular Response in CP-CML Patients Treated with Ponatinib or Imatinib
Authors: Justin R. Pritchard, Stephanie Lustgarten, Graeme Hodgson, Michele Baccarani, Jorge E. Cortes, Michael W. Deininger, Francois Guilhot, Andreas Hochhaus, Timothy P. Hughes, Neil P. Shah, Moshe Talpaz, Tim Clackson, Frank G. Haluska, Ronald Knickerbocker, Victor M. Rivera
Journal: Blood (2014)
FRI0542 Bioelectrical Impedance Analysis Is Not A Valid Method for The Assessment of Body Composition in Patients with Rheumatoid Arthritis
Authors: N. Konijn, L. van Tuyl, B. Dijkstra, I. Bultink, M. van der Schueren, W. Lems
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Rheumatoid cachexia (i.e. loss of fat free mass (FFM) and gain in fat mass (FM)) is often observed in chronic rheumatoid arthritis (RA) patients, with deleterious effects on morbidity and functional capacity [1,2]. In addition, the use of glucocorticoids is associated with increase in FM. Therefore, careful assessment of body composition is important in RA patients. Dual-energy X-ray absorptiometry (DXA) is a valid and reliable method to assess body composition, but is also expensive, time-consuming, invasive and thus not feasible for every-day use. Bioelectrical impedance analysis (BIA) is a relatively cheap, rapid, and non-invasive method to assess body composition in clinical practice, however BIA has not been validated in RA patients. <h3>Objectives</h3> To validate BIA against two different, widely used DXA devices for the assessment of body composition in patients with RA. <h3>Methods</h3> This cross-sectional validation study was performed in RA patients who visited study center A or B in the context of the COBRA-light extension studyl. Body composition was assessed by DXA (study center A: Hologic Delphi; study center B: GE Lunar IDxa) and BIA (Quadscan 4000) on the same day, and recorded as FM, FM%, FFM and FFM%. Agreement between both methods was assessed by paired t-tests, Bland-Altman plots and intra-class correlation coefficients (ICC), in which DXA was used as reference method. <h3>Results</h3> Of the 149 extension study patients, 43 patients (63% women, mean age 56 years, mean disease duration 5 years) were assessed by both DXA and BIA at the same day, and were included in this validation study. In study center A (n=25), BIA overestimated FM by 0.2 kg (p=0.71), and significantly underestimated FFM by 2.2 kg (p&lt;0.001). FM% and FFM% were respectively over- and underestimated by 1.1% (both p=0.05). In study center B (n=18), BIA systematically underestimated FM by 3.1 kg, and overestimated FFM by 2.2 kg; FM% and FFM% were respectively under- and overestimated by 3.6% (all: p&lt;0.001). Bland-Altman plots showed wide limits of agreement for all assessments in both study centers (Figure 1). These limits of agreement, indicating measurement error on individual level, were approximately 8 kg for FM and FFM assessments in both study centers. The ICC9s, indicating measurement error on group level, showed good agreement in study center A (&gt;0.90) and moderate-to-good agreement in study center B (&gt;0.85). <h3>Conclusions</h3> This study showed that BIA is an invalid method for the assessment of body composition in RA patients, both at individual and group level, and that errors depend on the DXA device used as reference method. <h3>References</h3> Walsmith, Int J Cardiol 2002, 85:89–99 Summers, Nat Rev Rheumatol 2010, 6:445–51 <h3>Disclosure of Interest</h3> None declared
AB0089 Non-Steroidal Anti-Inflammatory Drugs and Endothelial Function in Ra: Harmful or Beneficial? A Study in Rat Adjuvant-Induced Arthritis
Authors: F. Verhoeven, C. Prati, K. Maguin-Gate, P. Totoson, D. Wendling, C. Demougeot
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Rheumatoid Arthritis (RA) is associated with increased cardiovascular risk (CVR) explained in part by accelerated atherosclerosis as a consequence of endothelial dysfunction. Non-steroidal anti-inflammatory drugs (NSAIDs) are widely prescribed in RA patients in case of acute pain. Surprisingly, despite the commonly-held belief that NSAIDs worsen CVR, data regarding their effect on endothelial function in RA are lacking. <h3>Objectives</h3> The present study investigated the effect of naproxen (a non-selective COX inhibitor), diclofenac (a preferential COX-2 inhibitor) and celecoxib (a selective COX-2 inhibitor) on vascular function in arthritic rats and identified the underlying mechanisms. <h3>Methods</h3> Adjuvant-induced arthritis (AIA) was induced in 6 weeks-old male Lewis rats by injection of <i>Mycobacterium butyricum</i> in adjuvant at the basis of the tail. At the onset of arthritis, rats were daily treated (i.p.) with naproxen (10 mg/kg/d), diclofenac (5mg/kg twice a day), celecoxib (3 mg/kg/d) or saline (Vehicle) for 21 days. Arthritis scores were daily monitored. At the end of treatment, thoracic aortas were harvested to measure the relaxation to acetylcholine (Ach) on pre-constricted aortic rings in the presence or not of inhibitor of nitric oxide (NO) synthase (L-NAME), arginase (nor-NOHA), EDHF (Apamin/Charybdotoxin), or a superoxide dismutase analog (Tempol). The effects of a NO donor (sodium nitroprussiate, SNP) and norepinephrine (NE) were studied on endothelium-denuded aortic rings. <h3>Results</h3> All NSAIDs significantly reduced to the same extent arthritis score in AIA (p&lt;0.05). By contrast, differences exist between NSAIDs regarding endothelial function. Both naproxen and diclofenac significantly (p&lt;0.05) improved Ach-induced relaxation whereas celecoxib did not change the response to Ach. These differences on endothelial function were not explained by differences in the response of vascular smooth muscle to NE or SNP which remained unchanged after the 3 treatments. Of interest, the positive effects of naproxen and diclofenac likely relied on different mechanisms. Whilst naproxen tends to improve NOS activity and decrease superoxide anion production, diclofenac decreased arginase activity, superoxide anion production and improved EDHF production. <h3>Conclusions</h3> Our study demonstrates for the first time that naproxen and diclofenac have positive effects on endothelial function in case of arthritis whereas celecoxib had no effect, despite a similar reduction of inflammatory symptoms. From a clinical perspective, these data highlight the heterogeneity of effects of NSAIDs as regards CVR in RA and encourage designing clinical trials to confirm our experimental data and help guiding the better choice of NSAIDs for the global management of RA patients. <h3>Disclosure of Interest</h3> None declared
ACTR-02. AN MULTIVARIATE ANALYSIS FOR PROGNOSTIC SURVIVAL OF 121 ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Authors: Hui Ouyang
Journal: Neuro-Oncology (2016)

Additional criteria apply.Please refer to protocol 14379-201 for full inclusion and exclusion criteria.† Patients can participate if they had some skin cancers, superficial bladder cancer (cancer that was only on the surface of the lining of the bladder), or carcinoma in situ (cancer that had not spread) of the cervix or breast that had been cured.
One‐ or two‐week interval for variceal banding after bleeding: Which one to choose?
Authors: Ulku Saritas, Yucel Ustundag
Journal: Hepatology (2016)

Potential conflict of interest: Nothing to report. TO THE EDITOR: We read with great interest the article by Sheibani et al. comparing the 1‐week with 2‐week interval for ligation of esophageal varices after bleeding.1 They reported that at 4 weeks, 37 of 45 (82%) patients in the 1‐week interval group and 23 of 45 patients (51%) in the 2‐week interval group had succeeded in variceal eradication. They also noted that the 1‐week interval had more‐rapid variceal eradication than the 2‐week interval (18.1 vs. 30.8 days, respectively). This study is an important data source for correct programming of variceal eradication schedule in our patients. However, we have several concerns with this article. Given that it is well known, band ligation is the most common way of esophageal variceal eradication. Three or 4 days after banding, plastic bands slough off on necrotic tissue developing over the ligated area and then an ulcer appears and heals within 10 days.2 We usually wait for 2 weeks to continue ligation sessions given that band ulcerations heal completely during this period. This tradition is based on concerns for ulcer related bleeding. This study also confirms the increased risk of bleeding related to band ulcerations if the 1‐week interval is used given that this risk at 12 weeks was reported as 2 times higher than the risk associated with the 2‐week interval (9% vs. 4%, respectively). Furthermore, ligation sessions were postponed because of band ulcerations more often in patients undergoing the 1‐week, rather than the 2‐week, interval (22% vs. 9%, respectively). Although variceal eradication at 4 weeks was noted to be faster in the 1‐week group, the rebleeding rates at 1 month were not found to be lower than the 2‐week group (2% vs. 0%, respectively). Final variceal eradication rates were also found to be similar in both groups at the end of 8 and 12 weeks (93%‐84%, respectively). An important flaw with this information is that the researchers did not provide any data about the number of bands used in each session, which will automatically affect the variceal eradication rates in their patients. At 8 and 12 weeks of eradication, the researchers noted a little bit higher bleeding rates in the 1‐week than the 2‐week group. Another issue with 1 week was higher rates of dysphagia, odynophagia, and chest pain in this group of patients than the 2‐week group (9% vs. 2%, respectively). Thus, this study clearly shows us that the 1‐week interval, although seeming to have faster variceal eradication rates, is practically not superior to the 2‐week counterpart because it did not lower rebleeding rates at 4, 8, and 12 weeks of follow‐up and it resulted in more band ulcerations with more patients complaining of dysphagia, chest pain, and odynophagia.
Superior CMR-Rates with Tolerability-Adapted Imatinib 800 Mg Vs. 400 Mg Vs. 400 Mg + IFN In CML: The Randomized German CML-Study IV
Authors: Rüdiger Hehlmann, Susanne Jung-Munkwitz, Michael Lauseker, Martin C. Müller, Armin Leitner, Nadine Pletsch, Ulrike Proetel, Alois Gratwohl, Gerhard Ehninger, Dieter K. Hossfeld, Christoph Nerl, Hans Pralle, Dominik Heim, Gabriela M. Baerlocher, Leopold Balleisen, Hermann Einsele, Christiane Falge, Anthony D. Ho, Matthias Hänel, Michael Pfreundschuh, Lothar Kanz, Frank Stegelmann, Claus-Henning Köhne, Stephan Kremers, Karsten Spiekermann, Steffen Koschmieder, Cornelius F. Waller, Martin Bentz, Stefan W. Krause, Benjamin Hanfstein, Susanne Schnittger, Markus Pfirrmann, Jörg Hasford, Andreas Hochhaus, Susanne Saussele
Journal: Blood (2010)
FRI0556 Does Leaving Poverty Reduce Newly Accumulated Damage in SLE?: Table 1.
Authors: E. Yelin, L. Trupin, J. Yazdany
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Several studies indicate that persons with SLE in poverty experience increased levels of accumulated damage compared to the non-poor. However, it is unknown as to whether leaving poverty reduces the amount of newly accumulated damage and over what time frame. <h3>Objectives</h3> Describe impact of permanently leaving poverty on newly accumulated damage and the duration of time until the effects of poverty are attenuated. <h3>Methods</h3> We used the UCSF Lupus Outcomes Study (LOS), a national longitudinal sample of persons with SLE interviewed annually. The survey collects data to assess whether individuals are ≤125% of the US Federal poverty level as well as a validated self-report battery of accumulated damage, the Brief Index of Lupus Damage (BILD)<sup>1</sup>. We used linear regression to analyze the impact of having left poverty permanently versus having remained in poverty or never having been in poverty and effect of # of years out of poverty on change in BILD between the 2009 and 2014, with and without adjustment for covariates. Covariates are listed in the footnote to Table 1, below. <h3>Results</h3> 2009 LOS interviews included 750 persons with SLE, of whom 587 were interviewed through 2014. Of the 587, 461 (80%) were never in poverty between 2009 and 2014, 51 (9%) remained poor throughout, and 67 (12%) left poverty permanently. In 2009 mean BILD was 1.95 (std dev, 2.00), range 0–13; by 2014, mean BILD increase was 1.44 (std dev 1.71), range 0–13, a clinically meaningful increment in damage. Table 1 summarizes change in BILD as a function of having left poverty and for how long and shows that persons who left poverty experience similar levels of accumulated damage as those never in poverty; this occurs by 2–3 years after leaving poverty. <h3>Conclusions</h3> Leaving poverty is associated with reduced levels of newly accumulated damage as soon as 2–3 years later, even when taking into account disease, demographics, medical care, and health behaviors. These results indicate that clinicians should be attentive to the burdens associated with poverty and that public policies to alleviate poverty not specifically geared to persons with SLE may contribute to the reduction of new damage in SLE. <h3>References</h3> Yazdany J, et al. Arthritis Care Res (Hoboken). 2011 Aug;63(8):1170–7. doi: 10.1002/acr.20503. <h3>Acknowledgement</h3> Robert Wood Johnson Investigator Award in Health Policy and NIAMS P60-AR-053308 and 5R01AR56476 <h3>Disclosure of Interest</h3> E. Yelin Grant/research support from: NIAMS (NIH) and Robert Wood Johnson Foundation, L. Trupin Grant/research support from: NIAMS (NIH) and Robert Wood Johnson Foundation, J. Yazdany Grant/research support from: NIAMS (NIH) and Robert Wood Johnson Foundation
Transplantation of Positive Selected Peripheral Stem Cells with Add-Back of T Cells from Unrelated Donors in Children: Favourable Survival and Low Incidence of GvHD.
Authors: Peter J. Lang, Johann Greil, Peter Bader, Ulrike Mura, Michael Schumm, Tobias Feuchtinger, Matthias Pfeiffer, Rupert Handgretinger
Journal: Blood (2006)